NVSEF News and Press, Novartis Ag Basel Akt From 08/03/20

Quick Take Checkmate Pharmaceuticals ( CMPI ) intends to raise $75 million from the sale of its common stock stock in an IPO, according to an amended registration statement . The company is advancing a biologic particle treatment for melanomas and head & neck squamous cell carcinomas....

Gilead ( GILD ) - first, the bear case GILD reported Q2 results Thursday. The stock, which had begun underperforming the sector ( IBB ), dropped further, and on a weak day for biotech Friday closed down 3.9% at $69.53. After having led the sector up this year, it is now lagging IBB's to...

Quick Take Checkmate Pharmaceuticals ( CMPI ) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement . The company is a clinical stage biopharma advancing a drug treatment candidate for melanoma and head & neck cancer. CMPI has produ...

By Guney Kaya Novartis ( NVS ) has been a key pick for us during the coronavirus pandemic. Although a quintessential biopharma company, it has one of the safest pipelines with dozens of therapies already in registration phase or phase III. Their strategic shift to being a more value-add an...

Novartis AG (NVS) Q2 2020 Earnings Conference Call July 21, 2020, 8:00 am ET Company Participants Samir Shah - Global Head, IR Vas Narasimhan - CEO Harry Kirsch - CFO Marie-France Tschudin - President, Novartis Pharmaceuticals Susanne Schaffert - President, Novartis Oncology ...

Quick Take iTeos Therapeutics ( ITOS ) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a range of treatments for various cancers, including solid tumors. ITOS is pursuing treatments for...

The following slide deck was published by Novartis AG in conjunction with their 2020 Q2 earnings Read more ...

Quick Take Annexon ( ANNX ) intends to raise $150 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatments for autoimmune and neurodegenerative conditions. ANNX is pursuing multiple treatment programs with...

Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Quick Take ALX Oncology ( ALXO ) intends to raise $128 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for various blood and solid tumor cancer conditions. ALXO is pursuing treatments in...